NDAORALSOLUTION
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
POKONZA (potassium chloride) by Ascentage Pharma is (k+) is the principal intracellular cation of most body tissues. Approved for bowel preparation. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POKONZA is an oral potassium chloride solution approved in 2014 for bowel preparation and heart failure indications. It replaces depleted intracellular potassium and maintains essential physiological processes including nerve impulse transmission and cardiac muscle contraction. The drug works by supplementing the body's principal intracellular cation, restoring the critical potassium gradient across cell membranes.
Peak12.8 years to LOE
Peak lifecycle status indicates mature market presence; brand team likely focused on defensive positioning rather than growth expansion.
Mechanism of Action
(K+) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the…
Indications (1)
Worked on POKONZA at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.